Recommended Next Step: Switch to Mirtazapine
For a patient who has failed both an SSRI and SNRI with flu-like side effects (likely discontinuation symptoms) and persistent anxiety, depression, and insomnia, I recommend switching to mirtazapine as the next antidepressant. This addresses all three symptom domains simultaneously while avoiding the serotonergic side effect profile that has been problematic.
Rationale for Mirtazapine
Mirtazapine is specifically positioned as a sedating antidepressant with unique advantages for your patient's presentation:
- Addresses insomnia directly: Mirtazapine has 5-HT2 blocking properties that improve sleep architecture, shorten sleep-onset latency, increase total sleep time, and improve sleep efficiency 1, 2
- Different mechanism: As an atypical antidepressant with noradrenergic and specific serotonergic activity, it avoids the serotonergic side effects (including flu-like symptoms) common to SSRIs/SNRIs 3, 4
- Treats anxiety and depression: Effective for both conditions, particularly useful in agitated depression with insomnia 4
- Additional benefits: Promotes appetite and may help with weight gain if needed 4
Dosing Strategy
Start with 7.5 mg at bedtime, titrating up to a maximum of 30 mg at bedtime as tolerated 4. The sedating effect is most pronounced at lower doses, which is advantageous for your patient's insomnia.
Alternative Considerations Based on Guidelines
The guideline-recommended sequence for managing your patient's situation 1:
If insomnia is the primary concern: Consider short-intermediate acting benzodiazepine receptor agonists (zolpidem 10 mg, eszopiclone 2-3 mg, or zaleplon 10 mg at bedtime) 1
If switching antidepressants: The sedating antidepressants are specifically recommended when SSRIs/SNRIs have failed, especially with comorbid anxiety/depression 1. Options include:
Combination approach: If you choose to continue an SSRI/SNRI, adding trazodone for sleep is the most common practice—78% of psychiatrists surveyed chose this approach for SSRI-induced insomnia 5. However, given your patient's side effects, switching is preferable to polypharmacy.
Critical Management Points
Avoid these common pitfalls:
- Do not abruptly stop the current SNRI: Taper over 10-14 days to prevent worsening of discontinuation symptoms (the "flu-like" symptoms your patient experienced) 4, 6
- Do not use benzodiazepines long-term: While effective for acute insomnia/anxiety, they lead to tolerance, addiction, cognitive impairment, and paradoxical agitation in ~10% of patients 4
- Do not use antihistamines or herbal supplements: Over-the-counter sleep aids lack efficacy and safety data for chronic insomnia 1
- Monitor for weight gain: Mirtazapine is associated with weight gain and increased appetite 4
Concurrent Non-Pharmacological Treatment
Cognitive Behavioral Therapy for Insomnia (CBT-I) should be initiated alongside medication 1, 7. This is the standard of care and includes:
- Sleep restriction therapy
- Stimulus control
- Cognitive therapy
- Sleep hygiene (though not effective alone)
CBT-I facilitates eventual medication tapering and improves long-term outcomes 1. The combination of medication plus CBT-I is superior to either alone for patients with comorbid anxiety and depression 8, 9.
Follow-Up Schedule
Monitor the patient every few weeks initially to assess:
- Effectiveness on all three symptom domains (depression, anxiety, insomnia)
- Side effects (sedation, weight gain)
- Adherence to treatment 1
Aim to use the lowest effective maintenance dose and consider tapering when conditions allow, facilitated by ongoing CBT-I 1.
Why Not Other Options?
Switching to another SSRI: 61% of psychiatrists switch agents for SSRI-induced agitation 5, but your patient has already failed two serotonergic agents with side effects. Continuing in this class is unlikely to succeed.
SNRIs at high doses: Can cause hypertension and may worsen anxiety 3. Your patient has already tried this class.
Bupropion: While activating and useful for apathy, it would likely worsen insomnia and anxiety 4. Not appropriate for this presentation.